The functional role of respiratory microbiota has attracted an accumulating attention recently. However, the role of respiratory microbiome in lung carcinogenesis is mostly unknown. Our study aimed to characterize and compare bilateral lower airway microbiome of lung cancer patients with unilateral lobar masses and control subjects. Protected bronchial specimen brushing samples were collected from 24 lung cancer patients with unilateral lobar masses (paired samples from cancerous site and the contralateral noncancerous site) and 18 healthy controls undergoing bronchoscopies and further analyzed by 16S rRNA amplicon sequencing. As results, significant decreases in microbial diversity were observed in patients with lung cancer in comparison to the controls, alpha diversity steadily declined from healthy site to noncancerous to cancerous site. Genus Streptococcus was significantly more abundant in cancer cases than the controls, while Staphylococcus was more abundant in the controls. The area under the curve of genus Streptococcus used to predict lung cancer was 0.693 (sensitivity 5 87.5%, specificity 5 55.6%). The abundance of genus Streptococcus and Neisseria displayed an increasing trend whereas Staphylococcus and Dialister gradually declined from healthy to noncancerous to cancerous site. Collectively, lung cancer-associated microbiota profile is distinct from that found in healthy controls, and the altered cancer-associated microbiota is not restricted to tumor tissue. The genus Streptococcus was abundant in lung cancer patients and exhibited moderate classification potential. The gradual microbiota profile shift from healthy site to noncancerous to paired cancerous site suggested a change of the microenvironment associated with the development of lung cancer.
Introduction
The advent of next-generation sequencing techniques has debunked the long-held myth that the lungs are sterile in health. [1] [2] [3] Since the first culture-independent report of the microbiota in lower respiratory tract, 4 accumulating evidences now support potential functional roles for the lung microbiome. [5] [6] [7] [8] Dysbiosis of the lung microbiome can underlie lung diseases such as cystic fibrosis (CF), [9] [10] [11] asthma, 4, 12, 13 chronic obstructive pulmonary diseases (COPD), [14] [15] [16] bronchiectasis 17 or even lung cancer. 5, 18 However, the profile and functional role of bronchial bacterial colonization in patients with lung cancer remain largely unknown.
The microbiome has attracted an accumulating attention recently. In addition to the canonical risk factors, increasing efforts have been focused onto microbiome as a whole and its components as novel risk factors for cancer development. Molecular mechanisms linking specific microbes with colon carcinogenesis have also been identified. [19] [20] [21] [22] [23] For instance, in the gut, genotoxin producing Escherichia coli (E. coli), Enterotoxigenic Bacteroides fragilis (ETBF) and Fusobacterium nucleatum have been described to promote colorectal cancer (CRC) development via distinct mechanisms. [19] [20] [21] [22] [23] In addition, microbiome alteration may contribute to an established cancer's continued growth and spread, and vice versa. There is also accumulating evidence that the gut microbiome can also affect the response to anticancer therapies in multiple ways. 24 Conceivably, establishing the association of the microbiome with cancer may lead to significant advances in understanding of cancer etiology, cancer prognosis and cancer therapy, potentially opening a new research paradigm for the malignant diseases.
While studies targeting at the direct relationship between lung cancer and lung microbiome are quite limited at present, there have been interesting studies documenting persistent lung infections and inflammation can favor carcinogenesis. [25] [26] [27] [28] [29] [30] [31] [32] And certain types of microbial agents or products may positively or negatively modulate lung cancer development and/or progression. 27, 30, 32, 33 A large epidemiological study in humans suggested that the frequency of lung cancer increases upon use of repeated courses of antibiotics providing circumstantial evidence that some links may exist between the bacterial microbiota and lung cancer. 34 To date, three studies using highthroughput sequencing for bacterial identification characterized the lung microbiome in lung cancer patients, respectively using sputum samples, 18 tissue samples 5 and bronchoalveolar fluid samples (BALF). 7 All demonstrated the presence of lung bacterial communities among patients with lung cancer and altered lung microbiome in diseased state. Community diversity in the sputum was marginally lower in the lung cancer cases compared to healthy controls while no difference in diversity existed between patients with lung cancer and with benign disease using BALF. Decreased relative abundance of Spirochaetae and increased relative abundance of Firmicutes and TM7 were respectively detected in sputum samples and BALF samples in patients with lung cancer. The hitherto largest study on lung microbiome using lung tissues samples showed the difference between malignant and non-malignant tissue microbiota in lung cancer patients. However, related data based on non-malignant tissues in lung cancer patients may not be completely applicable to healthy subjects, which adding little information about alteration of lung microbiota between lung cancer patients and the healthy controls. 5 Altogether, Microbiota studies in lung cancer remain in its infancy. Given the small number, lacking of control groups or conflicting data in the aforementioned examples, the key next steps in understanding the role of lung microbiome and lung malignance remain in determining the membership of the lung microbiota in patients with, at risk for and/or without cancer. So we conducted our study to delineate lung microbiotas of cancerous/non-cancerous sites of lung cancer patients and healthy controls using 16S rRNA-based next-generation sequencing (NGS).We sought to define the possibly unique composition of microbiome in lung cancer patients. For the first time to our knowledge, we performed comparative analysis of the lung microbiome in the paired PSB (protected specimen brushing) samples from patients with lung cancer, and across with samples from "healthy" subjects.
Material and Methods

Subject recruitment and sample collection
The study was approved by the Ethics Committee of Ruijin Hospital Affiliated with Shanghai Jiaotong University School of Medicine (2016-NO-81) and informed consent was obtained from all subjects. Twenty-four lung cancer patients with unilateral lobar masses and 18 "healthy" controls were selected from patients consented to bronchoscopy examination at Ruijin Hospital. Medical history were collected from all subjects and a set of routine pre-procedure tests, including physical examination, electrocardiogram, pulmonary function test, computed tomography, routine blood count and blood coagulation function analysis, were carried out. The diagnosis of lung cancer was established by histological confirmation. The criteria for selecting controls were as follows: good physical status, no significant respiratory conditions and normal findings on pre-procedure examinations and the bronchoscopy. Bronchoscopy via the oral route was performed to obtain paired PSB samples in lung cancer patients (one from the cancerous lesion, the other from the contralateral noncancerous site) and 1 PSB sample from each control. All samples were immediately frozen and maintained at 2808C until further DNA extraction.
DNA extraction, 16S rRNA amplification and 16S rRNA sequencing Bacterial DNA was isolated from airway samples using beads-beating method as previous described. 35 The V3-V4 region of the bacterial 16S ribosomal RNA (rRNA) was amplified using nested PCR. Amplicons were sequenced using the Miseq platform. An expanded description of the methods and the primer sequences is available in the online supplement.
What's new? Infection and inflammation of the lung promote tissue microenvironments conducive to lung carcinogenesis. They also affect the lung microbiome, the community of microorganisms found on mucosal and epithelial surfaces in the lower respiratory tract. In this investigation of lower airway microbial communities recovered via bilateral protected specimen brushing, distinct differences were found in lower airway microbial communities in lung cancer patients vs. healthy controls. Cancer-associated microorganisms were found beyond cancerous sites, being evident particularly in oral samples. The findings provide new information on clinical characteristics of the lower airway microbiome in lung cancer.
Sequence data analysis
Clean data were extracted from Raw data using USEARCH 8.0 and the criteria were shown in the online supplement. Operational taxonomic units (OTUs) were classified based on 97% similarity after chimeric sequences removed using UPARSE (version 7.1 http://drive5.com/uparse/). The phylogenetic affiliation of each 16S rRNA gene sequence was analyzed by RDP Classifier (http://rdp.cme.msu.edu/) against the Silva (SSU123) 16S rRNA database using confidence threshold of 70%. Sample diversity metrics were assessed on the basis of the nonparametric Shannon-Wiener (SW) diversity index and Simpson diversity index. Both weighted and unweighted UniFrac were calculated in QIIME. The QIIME pipeline was also used to generate principal coordinate analysis (PCoA) plots to visualize the unweighted UniFrac dissimilarity. PERMANOVA was used to test for statistical significance between the groups using 10,000 permutations (QIIME package). The linear discriminant analysis (LDA) effect size (LEfSe) was used to detect taxa with differential abundance among groups. Bar plots, PCoA plots and receiver operating characteristics (ROC) curves and the area under the ROC curve (AUC) values were all generated in R (http://www.R-project.org/).
Results
Characteristics of the subjects
Forty-two adult subjects were enrolled, including 24 newly diagnosed primary lung cancer patients with unilateral lobar masses and 18 "healthy" controls without medical history of asthma, COPD or other chronic airway diseases and nonpathologic respiratory manifestations at the time of the study. No patients had received chemotherapy, radiation therapy, undergoing surgery or other treatments for lung cancer before bronchoscopy. All subjects currently lived in Shanghai. All PSB samples (n 5 66) were categorized into three groups, samples from cancerous site (T, n 5 24) and paired contralateral noncancerous site (TN, n 5 24) from lung cancer patients, "normal" samples from the controls (N, n 5 18). Demographic and clinical characteristics of all subjects are shown in Table 1 .
Since antibiotic use could potentially confound the identified changes in microbial community, we excluded subjects who received antibiotics in the prior 3 months and further categorized the remaining samples into three subgroups, To (n 5 13), TNo (n 5 13) and No (n 5 8).
Bacterial diversity analysis
To measure differences of taxonomic diversity among groups, the Shannon and Simpson diversity index were calculated. By comparison, taxonomic diversity was significantly different between T group and N group samples, while no significant difference were observed for diversity between T and TN groups or TN and N groups. Both the Shannon and Simpson index revealed that diversity was highest in N control group and gradually decreased from N group to TN group to T group (Fig. 1a) .
Similarly, subgroups analysis revealed significant difference in diversity between To group and No group and no significant difference in diversity between TNo group and No group. The TNo vs. To showed significant difference according to Shannon index, but not with Simpson index. Still, we observed a noticeable trend of diversity that diminished from No group to TNo group to To group (Fig. 1b) .
Bacterial community structure
To evaluate the similarities of all samples, ecologic distances, calculated on the basis of the unweighted UniFrac distances, were visualized by PCoA plot (Fig. 2) . There was no distinct separation between T group samples and N group samples or between TN group samples and N group samples when combining all samples, while paired T and TN groups were much closer to each other than to the control N group (Fig. 2a) . The PCoA plot in Figure 2b 
Differential microbiota compositions
To compare the relative contribution of different taxa, we used the LEfSE to detect taxa with differential abundance among three groups. A total of 30 different taxa at different levels with significant abundance differences across three groups were identified, of which nine differentially abundant taxa at genus level were noted, including genus Staphylococcus and Streptococcus in comparison of T to N group, Haemophilus, Streptococcus, Neisseria, Leptotrichia, Capnocytophaga, Selenomonas and Acinetobacter in comparison of TN to N group and genus Dialister in comparison of TN to T group (Fig. 3a) . At the Phylum level, there was a suggestion that a rare Candidate_division_TM7 (<0.05% on average in each community) is enriched in TN group compared to T group. Clear differences were not observed between other specific phyla between cancerous and non-cancerous site or control (Fig. 3a) .We further analyzed the differential abundance of nine discriminative genera across three groups using the nonparametric Mann-Whitney test and the most discriminative genera between N and T were Staphylococcus abundant in controls and Streptococcus abundant in lung cancer cases, respectively (Fig.  3b) . Among the nine discriminative genera, Staphylococcus and Dialister displayed a trend to decrease from N group to TN group to T group, whereas Streptococcus and Neisseria increased from N group to TN to T group. In the LEfSE analysis of three subgroups, similar differentially abundant genera were observed and the noted multiple differential microbial taxa were much more than the corresponding differential taxa when included all the subjects into analysis. Fifteen differential taxa displayed a trend to decrease from No to TNo to To group (11 Proteobacteria, 3 Bacteroidetes and 1 Firmicutes), whereas three increased from No to TNo to To group (3 Proteobacteria). Further and more detailed list of the observed differences between the three subgroups are provided in the online supplement (Fig. S1 ).
To measure how correctly the relative abundance of each genus could classify two groups of samples (T vs. N), we constructed a classifier using random forests technique and employed the ROC curve to evaluate classification performance of potential screening tools for distinguishing patients with lung cancer from control subjects (Fig. 4) . Prediction models based on the random forests algorithm suggested that genus Streptococcus (Fig. 4a) or the combination of three OTUs (OTU19, OTU594, OTU645) (Fig. 4b) have the highest area under curve (AUC) respectively based on the genuslevel or OTU-level relative abundances. The AUC value of genus Streptococcus was 0.693 and the combination of the three OTUs (OTU19, OTU594, OTU645) showed a higher AUC value (AUC 5 0.701). All the three OTUs came from genus Streptococcus.
Discussion
In our study, we characterized the lower airway microbiota at cancerous lesion from patients with lung cancer and compared them to samples from paired non-cancerous side as well as samples from "healthy" controls. Our analysis suggested that lower airway microbial communities of lung cancer were distinguishable from that of "healthy" controls and the altered lung microbiota composition of patients with lung cancer is not restricted to cancerous tissue. For the first time to our knowledge, we documented genus Streptococcus was abundant in lung cancer patients and exhibited moderate classification potential. Moreover, other key findings included that genus Streptococcus was higher in lung cancer patients, while Staphylococcus was higher in "healthy" controls. A gradual "shift" of airway microbiota profile in lower airway Tumor clinical stage, n (%) 
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samples from "healthy" control to noncancerous region to paired cancerous region was also observed. These data provided initial insights into lower airway microbial associations with lung cancer and highlighted the reciprocal impact between airway dysbiosis and lung cancer, which would pave the way for further exciting work in this area. Up to now, three studies using next-generation sequencing characterized the lung microbiome of lung cancer patients. In a small-size study of sputum sampling from eight neversmoking female lung cancer cases and eight never-smoking female controls in China, significant enrichment of Granulicatella, Abiotrophia and Streptococcus at genus-level were observed in lung cancer cases. 18 Genus Streptococcus was consistently abundant in case group in our study. Lee et al. 7 indicated that differences exist in the bacterial communities of patients with lung cancer and those with benign mass-like lesions and showed the potential of genera Veillonella and Megasphaera to serve as screening tool to predict lung cancer using bronchoalveolar fluid. The former study showed decreased community diversity in lung cancer patients, consistent with our findings. However, no difference in diversity was showed between the two groups in the latter one. Heterogeneity may rest with the geographical and ethnic differences, methodological variance and the representativeness of sample type or rationality of grouping design. More recently, Yu et al. 5 performed the hitherto largest study on lung microbiome, which included 165 non-malignant and 31 paired tumor samples in the microbial analysis. Decreased diversity in paired tumor is also consistent with our results. Our study provided powerful gist for characterizing the lung microbiome of non-malignant lung tissues in lung cancer patients. Nevertheless, comparison of non-malignant tissues and paired tumor samples were limited to bacterial diversity analyses in lung cancer patients, and our study lacked comparison to lung microbiome of healthy control subjects, which limited the ability to define the role of lung microbiome in lung cancer.
In our study, lower airway samples from cancerous site had significantly lower community diversity compared to samples from the control group. The finding is compatible with of the previous two studies of the microbial community in lung cancer using sputum and lung tissue samples. 5, 18 The consistent discrepancy in bacterial diversity demonstrates that the airway microbiota may shift in both quantitative and qualitative aspects under certain diseased conditions. These findings can be blended into a "cancer hygiene hypothesis" 36 to postulate that increased incidence of cancer may be associated with the increased hygiene/decreased exposure to specific microorganisms, similar to what is known for autoimmune diseases and allergies. However, we cannot fully rule out the alternative hypothesis that the observed diversity changes might be just a passive byproduct of tumor progression. Therefore, new, preferably longitudinal studies should be executed to further elucidate these intriguing questions.
In our study, we also provided evidence that lung cancerassociated microbiome was enriched in Streptococcus while depleted in Staphylococcus, which suggested deleterious role of Streptococcus and protective role of Staphylococcus in the development of lung cancer. In addition, the genus Streptococcus exhibited moderate classification potential. While normally harmless, these two genera (Staphylococcus and Streptococcus) are being growingly investigated in relationship to the development of cancer in different organ sites. 18, [37] [38] [39] [40] [41] [42] [43] These studies have shown conflicting descriptions of these colonizers in carcinogenesis. Hosgood et al. 18 reported enrichment of Streptococcus in lung cancer cases, consistent with our own findings, while Staphylococcus showed no significant differences between cases and controls. In a recent study evaluating cancer-associated microbiome in breast tissue, 37 women with breast cancer had higher relative abundances of Staphylococcus while healthy women had higher relative abundances of Streptococcus; Staphylococcus isolate cultured from breast tissue of breast cancer patients displayed the ability to induce DNA damage while Streptococcus exhibited anti-carcinogenic properties and may play a role in prevention. These conflicting associations of microbiome with cancer development could be attributable to the fact that bacterial metabolites function differently at different body sites. The finding that certain taxa might play distinct roles at different body niches suggested a similar organ specificity to microbial effects on carcinogenesis. 44 An alternative explanation is that Staphylococcus and Streptococcus all consist of a large numbers of pathogenic and non-pathogenic species; the current technology is generally much more effective in the identification of higher level taxonomic assignments. Thus, it was difficult to identify actual species or strains involved in carcinogenesis. Moreover, the balance between host and colonizer can be tipped in either direction by a range of factors that modify each of the previously described stages of attachment, growth and immune evasion. More specifically, Streptococcus could be invasive, targets host fibronectin and induces a cytokine response under certain circumstance. These actions have the potential to promote inflammation and further promote carcinogenesis. As reported previously, mechanism of DNA double-strand breaks caused by certain bacteria isolated from cancerous site could leads to carcinogenesis, [45] [46] [47] [48] these same mechanisms may be involved in airway microbiota dysbiosis and lung carcinogenesis. Additional work is required to further elucidate these ambiguous questions. In addition, our study first reported a gradual "shift" in the lower airway microbiota profile from "healthy" to noncancerous to cancerous samples; the altered lung cancer and all other samples collected from the same group. Bars indicate significant differences between groups (nonparametric Mann-Whitney test and significant differences by ***p < 0.001); (d) Mean unweighted intra-group UniFrac distance between each sample and all other samples collected from the same subgroup. Bars indicate significant differences between groups (nonparametric Mann-Whitney test and significant differences by ***p < 0.001). T: samples from the cancerous site of lung cancer patients, TN: samples from the contralateral noncancerous site of lung cancer patients, N: samples from the "healthy" controls; To: samples from the cancerous site of lung cancer patients who received no antibiotics in the prior 3 months, TNo: samples from the contralateral noncancerous site of lung cancer patients who received no antibiotics in the prior 3 months, No: samples from the "healthy" controls who received no antibiotics in the prior 3 months.
[Color figure can be viewed at wileyonlinelibrary.com] associated microbiota composition was not only restricted to cancerous tissue, but also existed in the undiseased mucosa of patients with lung cancer. Coincidentally, a gradual shift in microbiota profile from gastritis to pre-neoplastic lesion to cancer was also reported in previous work by Aviles-Jimenez et al. 49 Moreover, in a study comparing gut microbiota between patients with CRC, individuals with polyps and healthy controls, the microbiota showed significant difference between controls and cases, and between mucosal biopsies from subjects with polyps and controls, which suggested that a CRC-distinctive microbiota was already present and possibly involved in the early stages of cancer development. 50 Admittedly, the lower airway microbiota was clearly distinct from the stomach microbiota, and the three groups in our study are distinct from those of three different gastric disease states in Francisco's study. Further clarification for this gradual microbial "shift" in tumor development or progression and the probable underlying mechanisms is obviously required. However, these findings suggested a possible precedence of microbial changes over localized tumor changes and we may have encouragingly uncovered an important new prospect in a potential mechanism involved in the bacteriamediated carcinogenesis.
In our study, the prominent phyla in the lower airways was Firmicutes, followed by Bacteroidetes, Proteobacteria, Actinobacteria and Fusobacteria; the prominent genera in the lower airways included Streptococcus, Prevotella, Haemophilus and Neisseria (see Table SI in the online supplement).These phyla or genera were also dominated in oral samples of patients with lung cancer, 18 which presumably spread from the upper respiratory tract through dispersal by micro-aspiration or inhalation. [51] [52] [53] [54] [55] [56] Since the respiratory tract are covered in a continuous mucosal layer, and all bathed in mucus and saliva, shifts in one anatomical location may be associated with changes in others. 3 Previous research efforts regarding the relationship of the upper and lower respiratory tract microbiome in chronic obstructive pulmonary disease 57 and cystic fibrosis 58, 59 demonstrate considerable spatial heterogeneity in bacterial community composition within the lungs (and even lobes) of individual patients. 60 However, the composition of the respiratory microbiome in the upper and lower respiratory tree is very similar in the healthy subject. 3 While this has sparked much new interest, the data are currently sparse and inconsistent. Study comparing the microbiota of spatially separated sites of respiratory tract in lung cancer is currently lacking and relevant study concurrently collecting upper and lower airway samples from patients with lung cancer are in progress in our laboratory. In future studies, it may be useful to take upper respiratory tract samples alongside lung samples in the healthy and respiratory patients, which may tie together the complete picture of what a healthy or diseased microbial community can look like in the respiratory system. Due to the low yield of bacterial DNA and the high concentration of host genomic DNA in PSB samples, nested PCR was necessary to obtain sufficient amplicons while avoiding eukaryotic DNA contamination. While different bacterial taxa contain different copy numbers of the 16SrRNAgene, amplification bias is inevitable with current sequencing techniques, with some bacterial species being overrepresented or underrepresented. It may not be possible to claim that the bacterial abundances identified via 16S sequencing quantitatively represent the relative abundances of bacteria in the sample. However, previous studies compared a mock community of bacteria which contained equimolar concentrations of each bacterial species with a 1:100 dilution of the same mock community, apparent biases were far smaller in the low-concentration dilution group, which vindicates the use of nested PCR in amplifying lowbiomass samples. 61 Sze et al. 14 demonstrated findings that pyrotag analysis of the lung samples with and without nested PCR yielded indistinguishable community compositions. In our study, sequencing results of the positive control sample with the general One-Round PCR method and nested PCR method showed great similarities in alpha diversity (see Table  SIV in the online supplement) and microbial abundance profiles (see Fig. SV in the online supplement) and the nested PCR was concluded not to bias 16S rRNA gene sequencing. These results further supported the nested PCR an appropriate method for bacterial community analysis of lung samples. Besides, as the same methodology is used for all samples within our study, it seems logical to assume that the biases present are the same for all samples. Therefore, comparisons of bacterial community present in samples between groups would be valid.
Given the static nature of descriptive study, whether the observed microbiome changes are part of the causative mechanism, a consequence of disease, or an epiphenomenon remains a question for future research. While meta'omics studies provide great insight into the microbiota associated with lung cancer development and progression, better tools are needed to parse the individual functions of specific microbes in the tumor microenvironment and provide clues for potential underlying mechanisms. Our study included genomic DNA from both viable and non-viable microbial cells which may result in overestimation of the underlying diversity; Besides, although related subgroup analysis stratified by usage of antibiotic, tumor stage, smoking status and pathologic type was conducted (online supplement), information about the association of microbiota to these epidemiological or clinical characteristics were limited due to the small sample size of this case study. Furthermore, divergences of microbiota between different clinical features highlight the need for future studies with larger sample sizes and inclusion and comparisons of subjects from various demographics and clinical features. Future studies should also incorporate the study of fungi, protists and viruses, in addition to bacterial community, to fully characterize the airway microbiome and its relationship with lung disease. Despite these considerations, our study represented a significant first step in understanding the lower airway microbiome and its potential contribution to lung cancer development.
In conclusion, we found that the lower airway microbial communities of lung cancer are distinguishable from that of "healthy" controls, and the altered cancer-associated microbiota is not restricted to tumor tissue. The genus Streptococcus was abundant in lung cancer patients and exhibited moderate classification potential. These findings suggested possible deleterious effects of airway microbial dysbiosis on malignant disease and potential use for prevention, diagnosis and treatment strategies targeting the airway microbiota.
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